Eli Lilly Designs P-Tau Biomarker Assay for Early Alzheimer’s Disease Diagnosis
The Pharma Data
NOVEMBER 10, 2020
Biomarkers will be critical to developing precision medicine for Alzheimer’s disease. Although a few are out there, phosphorylated tau (P-tau) may enable even earlier and more accurate detection, according to Eli Lilly-associated researchers speaking at the Clinical Trials on Alzheimer’s Disease (CTAD) virtual conference in early November.
Let's personalize your content